Jun. 25 at 6:11 PM
$NNOX For years, NNOX has thrived on hype, flashy presentations, and vague promises of revolutionizing medical imaging — yet we still haven’t seen meaningful commercial traction.Where are the hospitals? Where are the real-world deployments? Where is the revenue?Instead of solid execution, we’re getting press releases full of jargon and acquisitions that look more like desperate distractions than strategic moves. Their so-called “AI platform” sounds more like a marketing buzzword than a functioning, scalable product.
If you peel back the layers, this isn’t a medical imaging disruptor — it’s a glorified prototype factory with a nice slide deck.
Investors didn’t sign up to fund endless R&D experiments and speculative pivots. We backed this company to see clinical value, commercial growth, and technological substance.
Right now, all we’re getting is dilution, delay, and disappointment.
If NNOX truly believes in its mission, it’s time to stop selling hope — and start delivering results.
